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Background: Nitric oxide (NO) is cardioprotective and a mediator of ischemic preconditioning (IP). Endothelial
nitric oxide synthase (eNOS) is protective against myocardial ischemic injury and a component of IP but the role
and location of neuronal nitric oxide synthase (nNOS) remains unclear. Therefore, the aims of these studies were
to: (i) investigate the role of nNOS in ischemia/reoxygenation-induced injury and IP, (ii) determine whether its
effect is species-dependent, and (iii) elucidate the relationship of nNOS with mitoKATP channels and p38MAPK, two
key components of IP transduction pathway.
Results: Ventricular myocardial slices from rats and wild and nNOS knockout mice, and right atrial myocardial slices
from human were subjected to 90 min ischemia and 120 min reoxygenation (37°C). Specimens were randomized
to receive various treatments (n = 6/group). Both the provision of exogenous NO and the inhibition of
endogenous NO production significantly reduced tissue injury (creatine kinase release, cell necrosis and apoptosis),
an effect that was species-independent. The cardioprotection seen with nNOS inhibition was as potent as that of
IP, however, in nNOS knockout mice the cardioprotective effect of non-selective NOS (L-NAME) and selective nNOS
inhibition and also that of IP was blocked while the benefit of exogenous NO remained intact. Additional studies
revealed that the cardioprotection afforded by exogenous NO and by inhibition of nNOS were unaffected by the
mitoKATP channel blocker 5-HD, although it was abrogated by p38MAPK blocker SB203580.
Conclusions: nNOS plays a dual role in ischemia/reoxygenation in that its presence is necessary to afford
cardioprotection by IP and its inhibition reduces myocardial ischemic injury. The role of nNOS is species-
independent and exerted downstream of the mitoKATP channels and upstream of p38MAPK.
Background
It is well established that enhanced bioavailability of
endogenous nitric oxide (NO) affords cardioprotection
against ischemia and reoxygenation-induced injury [1].
This important mediator is enzymatically produced by
t h eN O - s y n t h a s e s( N O S s ) .T h e r ea r et h r e eN O Si s o -
forms, widely distributed through most cells and tissues,
which can produce NO by converting L-arginine to
L-citruline in the presence of NADPH, O2 and other co-
factors [2]. The endothelial NOS (eNOS) and neuronal
NOS (nNOS) are constitutive and Ca++-dependent
whereas the expression of the inducible NOS (iNOS) is
Ca++-independent and stress-induced.
It has been documented that nNOS is located in the
peripheral vagal nerves, sympathetic nerves and in the
autonomic control region of the central nervous system
[2]. In cardiomyocytes, nNOS is expressed in sarcoplas-
mic reticulum, sarcolemma and mitochondria [3-5]. NO
d e r i v e df r o mn N O Si n f l u e n ces the beat to beat regula-
tion of basal cardiac function, serving negative feedback
control of Ca
++ fluxes [6,7]. In addition, it facilitates
vagal stimulation and inhibits sympathetic stimulation
by exerting its effect in the central and peripheral
nervous system.
NO derived from eNOS is essential for eliciting early
ischemic preconditioning (IP) [8], however, there is still
c o n t r o v e r s ya b o u tt h er o l eo fn N O S .T h u s ,a l t h o u g h
nNOS expression is increased in the acute phase of
myocardial infarction in both infarcted and non-
infarcted tissues in the rat heart [9], it has been reported
that in the nNOS knockout mice, there is no change in
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any medium, provided the original work is properly cited.myocardial infarct size [10,11]. By contrast, it appears
that delayed IP (72 hours) is dependent on nNOS in the
rabbit [12], whereas the deficit of nNOS reduces cere-
bral ischemic injury in mice [13].
MitoKATP channels, located in the inner mitochondrial
membrane, are central for IP [14]. Few studies have
shown a link between mitoKATP and NO in IP. Sasaki et
al suggested that NO causes the opening of mitoKATP
directly and indirectly [15] which in turn induces blunt-
ing of the Ca
++ overload in mitochondria, thus contri-
buting to the delayed IP. It has also been reported that
the opening of the mitoKATP channels by diazoxide
induces cardioprotection in a NO-dependent manner
[16]. Furthermore, Rakhit et al have demonstrated that
the exogenous NO donor SNAP induces early IP by a
cGMP-dependent mechanism and delayed IP by a
cGMP-independent mechanism which is mediated by
activation of PKC and mitoKATP channels [17]. Interest-
ingly, Nakano et al suggested that SNAP-induced cardi-
oprotection cannot be reproduced by endogenous NO
[18] also implying that there are two separate pathways
for NO-induced cardioprotection.
Our laboratory has previously demonstrated that
opening of p38MAPK is an obligatory step in IP that
lies downstream of PKC activation [19]. However, there
is little information regarding the relationship of NO
with p38MAPK in the myocardium. Thus, for example,
Kim et al. showed that sodium nitroprusside activates
p42/44 and p38MAPK in adult rat cardiomyocytes via
both cGMP-dependent and cGMP-independent
mechanisms [20]. In another study, Wang et al demon-
strated that NO suppressed the angiotensin-I induced
activation of ERK in cardiac fibroblast [21]. Other stu-
dies carried out in non-cardiac mitogenic cells have
shown that NO induced apoptosis is mediated directly
by activation of MAPK [20-22]. So, the relationship of
NO with p38MAPK remains largely undefined.
Therefore, the aims of the present studies were to: (i)
elucidate the role of nNOS in ischemia/reoxygenation-
induced injury and IP, (ii) determine whether its effect
is species-dependent, and (iii) investigate the relation-
ship of nNOS with mitoKATP channels and p38MAPK,
two key components of the intracellular transduction
pathway of protection by IP.
Results
Myocardial viability, as assessed by the absence of
necrosis and apoptosis by the end of the experimental
period in aerobically incubated myocardial slices, was
greater than 95% in all instances.
(i) The role of nNOS in ischemic injury
Figures 1a-c show that, in the rat myocardium, the
selective inhibition of nNOS by TRIM resulted in a
Figure 1 CK release (a), and cell necrosis (b) and apoptosis (c)
in rat ventricular myocardium subjected to 90 min ischemia
followed by 120 min of reoxygenation (n = 6/group).
Specimens were incubated with SNAP, L-NAME or TRIM for 20 min
prior to ischemia. *P < 0.05 vs. ischemia/reoxygenation (I/R) alone;
†P < 0.05 vs. SNAP and TRIM treated groups.
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and apoptosis, as compared to the mean values in the
ischemia/reoxygenation alone group. The degree of this
protection was similar to administration of exogenous
NO but greater than the non-selective NOS inhibitor L-
NAME.
(ii) Is the role of nNOS species-dependent?
As seen in Figures 2a-f, and in comparison with the
results observed in Figures 1a-c, the order of magnitude
of ischemic injury for CK release and cell necrosis and
apoptosis varied slightly between species, however, iden-
tical effects on NOS inhibition and from the administra-
tion of exogenous NO to that seen in rat myocardium
(Figures 1a-c) were observed for both mouse and
human myocardium.
(iii) Knocking out nNOS
Figures 3a-c demonstrate that, as opposed to wild type
mice, the myocardium of nNOS knockout mice could
not be protected by the specific NOS inhibitor TRIM as
the mean values for CK release and cell necrosis and
Figure 2 CK release (a), and cell necrosis (b) and apoptosis (c) in mouse ventricular myocardium and CK release (d), and cell necrosis
(e) and apoptosis (f) in human right atrial myocardium subjected to 90 min ischemia followed by 120 min of reoxygenation (n = 6/
group). Specimens were incubated with SNAP, L-NAME or TRIM for 20 min prior to ischemia. *P < 0.05 vs. ischemia/reoxygenation (I/R) alone;
†P < 0.05 vs. SNAP and TRIM treated groups.
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subjected to ischemia/reoxygenation alone. The absence
of benefit when L-NAME was added to the myocardium
of knockout nNOS mice supports the thesis that
although the endogenously produced NO by eNOS may
be beneficial its deficit did not cause further ischemic
injury. As seen above, again the NO donor SNAP almost
abolished the CK release and the cell death induced by
ischemia and reoxygenation. Importantly, and in con-
trast with wild type mice, the myocardium of nNOS
knockout out mice could not be protected by IP since
the mean values for CK release and cell necrosis and
apoptosis did not differ from the values in the ischemia/
reoxygenation alone group. However, the degree of
injury in the ischemia-reoxygenation alone groups was
similar in both wild type and nNOS knockout mice as
previously reported [10].
(iv) The relationship of exogenous NO and nNOS
inhibition with mitoKATP channels and p38MAPK
Figures 4a-c demonstrate that the reduction in CK
release and in cell necrosis and apoptosis caused by the
NO donor SNAP and the inhibition of nNOS with
TRIM, was unaffected by the mitoKATP channel blocker
5-HD, and that, as expected, it blocked the protection
by IP. By contrast, Figures 5a-c show that the
p38MAPK blocker SB203580 abolished the protective
effect of exogenous NO and of nNOS inhibition, along
with the benefit of IP.
Figure 3 CK release (a), and cell necrosis (b) and apoptosis (c)
in nNOS knockout mice ventricular myocardium subjected to
90 min ischemia followed by 120 min of reoxygenation (n = 6/
group). Specimens were incubated with SNAP, L-NAME or TRIM for
20 min prior to ischemia. For comparison, some muscles were
subjected to ischemic preconditioning (IP). *P < 0.05 vs. ischemia/
reoxygenation (I/R) alone.
Figure 4 CK release (a), and cell necrosis (b) and apoptosis (c)
in rat ventricular myocardium subjected to 90 min ischemia
followed by 120 min of reoxygenation (n = 6/group).
Specimens were incubated with SNAP or TRIM for 20 min prior to
ischemia in the absences and presence of 5-HD. For comparisons,
some muscles were subjected to ischemic preconditioning (IP) in
the absences and presence of 5-HD. *P < 0.05 vs. ischemia/
reoxygenation (I/R) alone.
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The present studies have demonstrated that nNOS plays
a dual role so that its presence is necessary to afford
c a r d i o p r o t e c t i o nb yI P ,b u ta tt h es a m et i m ei t si n h i b i -
tion reduces myocardial ischemic/reoxygenation induced
injury. In addition, they have shown that the protection
obtained by the inhibition of nNOS is as potent as the
exogenous administration of NO and that of IP, effects
that are species-independent. Importantly, the action of
nNOS and those of exogenous NO are exerted down-
stream of mitoKATP channels and upstream of p38
MAPK.
The duplicity of nNOS-derived effects seen in our stu-
dies can be explained, on one hand by a physiological
production of NO that triggers the cardioprotective
intracellular mechanism of interventions such as IP, and
on the other hand by a possible much greater produc-
tion of NO induced by ischemia/reoxygenation that is
detrimental. In this connection, other investigators have
also reported in an infarct size model that nNOS plays
an opposite role in ischemia/reperfusion and IP [23] and
that the protection of delayed IP in the rabbit heart is
dependent on nNOS [12]. Since NO donors such as
SNAP also have strong cardioprotective effects, it may
be speculated that the amount and cell location of NO
production would determine whether the final result is
tissue protection or injury. It is also interesting to note
that myocardial injury (CK release and cell death) was
not increased by ischemia/reoxygenation in nNOS
knockout mice, a finding supported by the absence of
changes in infarct size in nNOS knockout mice [9,11].
By contrast, a deficit in nNOS in mice reduced the
degree of cerebral ischemic injury [13], thus suggesting
that the role of nNOS in ischemia/reoxygenation could
be organ-specific.
Our studies locate the action of nNOS downstream of
the mitoKATP channels since the protection induced by
nNOS specific inhibitor TRIM was blocked by 5-HD, a
mitoKATP channel inhibitor. The finding that exogenous
NO is also acting at the same point reinforces the view
that the production of endogenous NO by nNOS is the
mechanism of protection. Indeed, other laboratories
have shown that the protection induced by exogenous
NO is not affected by blockade of mitoKATP channels
with 5HD or glibenclamide [17] and that the protection
induced by the mitoKATP channel opener diazoxide is
NO-dependent [14], further supporting the thesis that
NO metabolism is a critical component of the cell survi-
val mechanism. The different location of the two consti-
tutive forms of NOS, nNOS and eNOS, may also
suggest that NO plays a distinctive role depending on
the cellular site where it is produced. This thesis gets
s u p p o r tf r o mt h ef i n d i n gt h a tt h es p e c i f i ci n h i b i t i o no f
nNOS was more protective than the non-specific inhibi-
tion of NOS. Certainly, this is an important question
that would require further investigations.
Previously, our laboratory has shown that p38MAPK
is another critical factor of IP-induced cardioprotection
located beyond the mitoKATP channels [19,24]. Here we
have also shown that the effect of NO metabolism in
the intracellular signaling pathways of cardioprotection
is exerted upstream of p38MAPK, as the beneficial
effects of exogenous NO donation and nNOS inhibition
were abolished by the p38MAPK blocker SB203580.
These findings are supported by the demonstration of
protection of cardiac [20] and non-cardiac cells [22,25],
Figure 5 CK release (a), and cell necrosis (b) and apoptosis (c)
in rat ventricular myocardium subjected to 90 min ischemia
followed by 120 min of reoxygenation (n = 6/group).
Specimens were incubated with SNAP or TRIM for 20 min prior to
ischemia in the absences and presence of SB203580 (SB). For
comparisons, some muscles were subjected to ischemic
preconditioning (IP) in the absences and presence of SB203580. *P
< 0.05 vs. ischemia/reoxygenation (I/R) alone.
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MAPKs.
An additional important finding is the identical role
played by nNOS in the three species studied (rat, mouse
and human), suggesting that the function of the enzyme
has been preserved throughout evolution. These results
may have clinical implications since the findings
observed from the animal studies could be extrapolated
to human beings without the need for additional confir-
matory investigations. Nonetheless, it is worth empha-
sizing that the present studies were performed in an
in vitro model and therefore care must be taken when
extrapolating the present results to clinical conditions.
However, despite the differences between atrial and ven-
tricular samples, the myocardium from the mouse and
rat ventricles and from the human right atrial appen-
dage, responded in a similar manner and hence the dif-
ferent source of myocardium should not represent a
problem for the interpretation of the results. During car-
diac surgery, myocardial ischemia is induced in a con-
trolled manner and therefore it would be possible to
enhance cardioprotection by manipulation of the NO
metabolism. However, in the clinical setup, the heart
may be subjected to stresses that can result in the
expression of the inducible NOS (iNOS) and it would
be important to elucidate the role of the constitutive
NOS isoforms, nNOS and eNOS, in the pathophysiology
of ischemia/reperfusion-induced injury under such con-
ditions. It is worth emphasizing that, although the activ-
ity of nNOS has been shown to be increased in the late
phase of delayed IP[12], to the best of our knowledge,
the activity of the enzyme has not been determined in
early IP. Indeed, it would be important to determine the
activity of all NOS isoforms in future studies.
In conclusion, here we have shown that nNOS is a
critical factor playing a dual role by participating in
myocardial ischemia/reoxygenation injury, and at the
same time, by promoting myocardial protection. These
results are of clinical relevance for the design of thera-
peutic interventions aimed at reducing the myocardial
damage caused by ischemia/reoxygenation.
Methods
Procurement of myocardial samples
Wister rats and C57BL/6J mice were purchased from
Charles Rivers UK Ltd (Kent, UK). nNOS knockout
mice (C57BL/6J) were also obtained from The Jackson
Lab (Bar Harbor, Maine, USA). Animals were culled by
cervical dislocation and the heart was rapidly dissected
and sectioned as described below. These studies were
undertaken in accordance with the guidelines on the
Operation of Animals (Scientific Procedure) Act 1986.
All procedures are approved by the Animal Care and
Use Committee of the University of Leicester.
The right atrial appendage from patients undergoing
elective heart surgery for coronary bypass surgery or
aortic valve surgery was obtained prior to the initiation
of cardiopulmonary bypass. Patients with atrial fibrilla-
tion, cancer, diabetes, poor LV function (EF < 30%) or
with additional surgical procedures or those being trea-
ted with opioids, catecholamines, or the mitoKATP chan-
nel opener nicorandil were excluded from the study.
The study was conducted according to Declaration of
Helsinki principles and approval was obtained from the
Local Ethics Committee. All participants provided
informed written consent.
Experimental model and preparation of myocardial
samples
The experimental preparation has been previously
described and characterized [26,27]. Briefly, upon har-
vesting, samples (rats and mice hearts and human right
atrial appendages) were immediately immersed in cold
( 4 ° C )K r e b s / H e n s e l e i t / H e p e s( K H H )b u f f e r e dm e d i u m
containing (in mM): NaCl 118, KCl 4.8, NaHCO3 27.2,
KH2PO4 1, MgCl2 1, CaCl2 1.25, Glucose 10 and Hepes
20, pre-bubbled with 95% O2/5% CO2 and at a pH of 7.4.
Specimens were immediately sectioned manually with a
skin-graft blade (Swann-Morton Ltd, Sheffield, U.K.) to
slices of 30-50 mg weight and 300-500 μm thickness. The
specimens and the apparatus were kept wet during sec-
tioning with cold and oxygenated medium. After this,
specimens were equilibrated under normothermic aero-
bic conditions (95% O2/5% CO2) for 50-60 min, and then
subjected to 90 min of simulated ischemia at 37°C,
obtained by continuously bubbling the media with 95%
N2/5% CO2 in the absence of glucose and at a pH of 6.8,
followed by 120 min reoxygenation. Time matched aero-
bic controls were used in every experiment.
For the induction of IP, specimens were subjected to 5
min ischemia followed by 5 min reoxygenation prior to
induction of the 90 min ischemia, a protocol that
induces maximal protection in this in vitro preparation
[28]. Reagents were incubated with the specimens prior
to ischemia, during ischemia, or during reoxygenation in
the manner and at the doses described below in the
study protocols.
Assessment of myocardial injury
Myocardial injury was assessed by measurement of crea-
tine kinase (CK) release into the media during the
120 min reoxygenation period. The enzyme activity was
measured by an ultraviolet method based on the forma-
tion of NADP employing a commercial assay kit
(30-3060/R2: Abbott Laboratories, Diagnostic Division,
Kent, UK) and a 96 well flat-bottom micro plate (Costar,
Corning Life Sciences, Lowell, Massachusetts, USA). In
this assay, NADP is reduced to NADPH and absorbance
Barua et al. BMC Physiology 2010, 10:15
http://www.biomedcentral.com/1472-6793/10/15
Page 6 of 8at 340 nm was measured using a spectrophotometer
(Benchmark, Bio-Rad Laboratories, California, USA).
Results were expressed as IU/mg wet weight.
Assessment of cell death
At the end of the experimental protocol, specimens
were incubated for 15 min at room temperature on a
rocker with 20 μg/ml propidium iodide (PI, Sigma-
Aldrich, Dorset, UK) in phosphate buffered saline (PBS)
at a pH of 7.4, to identify the necrotic nuclei. Specimens
were then washed with PBS twice for 5 min each time
before fixation in 4% paraformaldehyde. They were kept
overnight at 4-10°C and then transferred to sucrose 30%
until the tissue sank. All the above steps were performed
in the dark to avoid exposure to light. Following this,
the specimens were embedded with Optical Cutting
Temperature embedding matrix (Tissue-Tek®, Agar
Scientific Ltd, Essex, UK). Frozen sections were then cut
at 7 μmt h i c k n e s si naB r i g h tc r y o t o m e( m o d e lO T F )a t
circa -25°C, and sections were collected on SuperFrost
Plus slides (Menzel Glasser, Braunschweig, Germany).
During the preparation of slides, the periphery of speci-
mens were discarded because this area may be more
s u s c e p t i b l et od a m a g eb yt h eh a n d l i n g .T h es l i d e sw e r e
then kept at -80°C until further analysis.
To assess apoptosis, the slides were brought from -80°C
to room temperature, washed with 20 mM PBS, and then
permeabilised for 1 minute in a microwave oven at 850
watts in 200 ml of 0.1% Triton X-100 in 0.1 M Tri-
sodium citrate buffer at a pH of 6.0. After this, the slides
were rapidly cooled by adding 80 ml distilled water and
transferred to 20 mM PBS solution. In addition, they
were immersed into 3% bovine serum albumin (Sigma
Aldrich, Dorset, UK) in 0.1 M Tris-HCl buffer with 20%
fetal bovine serum (Hyclone, Utah USA) at a pH of 7.5
for 30 min to block unspecific labeled activity. The term-
inal deoxynucleotidyl transferase (TdT) was used to
incorporate fluorescein (FITC) labelled dUTP oligonu-
cleotides to DNA strand breaks at the 3’-OH termini in a
template dependent manner (TUNEL technique) for 90
min at 37°C in a humidity chamber using a commercially
available kit (Roche Diagnostics, Penzberg, Germany).
To distinguish the total number of nuclei, sections
were counter-stained with 1 μg/ml 4′, 6-Diamidino-2-
phenylindole (DAPI) (Molecular Probes, Eugene, Ore-
gon, USA) in PBS for 1 min. Then the slides were
washed 3 times for 5 min each in PBS. To reduce
photobleaching, the sections were mounted with anti-
fade solution (Prolong Antifade kit, Molecular Probes,
Eugene, Oregon, USA) and covered with coverslips
(Menzel Glasser, Braunschweig, Germany).
A fluorescent microscope (Axiovert 200 M, Zeiss
fluorescent microscope, Göttingen, Germany) at 40×
magnification was used to assess necrosis and apoptosis.
At least ten fields per section, and one section per stain-
ing, were examined for each experiment. The fields
were measured following the horizontal and vertical
axes of the sections. PI and FITC labelled nuclei were
detected by the Cy3 and EGFP channels respectively,
whilst DAPI labelling was detected by the DAPI chan-
nel. Only the necrotic or apoptotic signals coinciding
with DAPI were considered true events. The NIH Image
software (Scion Corp, Frederick, Maryland, USA) was
used to determine the total events for each field. To
avoid the inclusion of artefacts, only fluorescent signals
with areas greater than 16 μm
2 were counted.
Study protocols
In each study, specimens were randomly allocated to
different groups (n = 6/group) and specimens from one
single donor were not utilized twice for the same group.
Some specimens were aerobically incubated for the
whole experimental time under aerobic conditions; and
others, subjected to 90 min ischemia/120 min reoxy-
genation alone, served as ischemic controls. The follow-
ing studies were sequentially carried out:
(i) Study 1: The role of nNOS in ischemic injury
To investigate this, specimens from ventricles of rat
hearts were randomized to receive the exogenous NO
donor SNAP (100 μM), the non-selective NOS inhibitor
L-NAME (100 μM), or the selective nNOS inhibitor
TRIM (100 μM), for 20 min prior to ischemia. The
selected concentrations of the agents used were found
to be optimally effective in previous studies [26,28].
(ii) Study 2: To elucidate whether the role of nNOS is
species-dependent
This was achieved by applying a protocol identical to
study 1 to specimens from mice hearts and from human
right atrial appendages.
(iii) Study 3: To further characterize the role of nNOS using
nNOS knockout mice
In this study, nNOS knockout mice were used to further
characterize the role of nNOS following a protocol iden-
tical to the one in study 1. IP was also applied in a
group of specimens. In addition and for comparison,
ischemia/reperfusion alone and IP were induced in spe-
cimens from wild type mice.
(iv) Study 4: To investigate the location of the action of
exogenous NO and of nNOS inhibition in relation to
mitoKATP channels and p38MAPK
For this study, myocardial slices were obtained from rat
ventricles. Specimens were randomized to receive the
NO donor SNAP (100 μM), or the selective nNOS inhi-
bitor TRIM (100 μM), for 20 min prior to ischemia in
the absence and presence of the mitoKATP channel
blocker 5-HD (1 mM) or the p38MAPK inhibitor
SB203580 (10 μM )f o r3 0m i n .I na d d i t i o n ,s o m ep r e -
parations were subjected to IP.
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Data are expressed as mean ± SEM. Each reported value
was obtained after subtracting the corresponding time-
matched aerobic control value. One way ANOVA, fol-
lowed by Bonferroni’st e s t ,w a su s e dt oc o m p a r et h e
significance between groups. Analyses were performed
using the SPSS program. Differences were considered to
be statistically significant if p < 0.05.
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